Advanced Medical Solutions Group plc
("AMS", the "Company"
or the "Group")
Director/PDMR Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing
technologies, announces that on 23 April 2024, the Board, following a recommendation from
its Remuneration Committee, granted new nil-cost share options to
the following Directors/PDMRs under the existing Advanced Medical
Solutions Long Term Incentive Plan (the 'LTIP'). The vesting of
these options is based on achieving certain performance criteria
for the three years prior to vesting. The performance criteria
under the LTIP scheme is split equally
between Earnings Per Share (EPS) achievement against target and
Total Shareholder Return (TSR) against a comparator group.
Directors/PDMRs are required to hold the LTIPs for a period
of two years following vesting.
|
Director/PDMR
|
LTIPs prior to grant
|
LTIPs granted
|
Resultant LTIP holdings
|
|
Chris Meredith
Chief Executive Officer
|
935,567
|
411,478
|
1,347,045
|
|
Eddie Johnson
Chief Financial Officer
|
417,032
|
169,837
|
586,869
|
The notification below, made in
accordance with the requirements of the EU Market Abuse Regulation,
provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1.
|
Details of the person discharging
managerial responsibilities/person closely
associated
|
|
a)
|
Name: Chris Meredith
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status: Chief
Executive Officer
|
|
b)
|
Initial
notification/Amendment: Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name:
Advanced Medical Solutions Group plc
|
|
b)
|
LEI: 213800HJP6OWOSZI1L74
|
4.
|
Details of the transaction(s): section
to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the
financial instrument, type of instrument: Ordinary Shares of
5p
Identification code:
GB0004536594
|
|
b)
|
Nature of the
transactions:
- Grant of options under the Advanced Medical Solutions Long Term Incentive
Plan
|
|
c)
|
Price(s) and
volume(s):
Sale of
shares:
|
Price(s)
|
Volume(s)
|
|
1. -
|
411,478
|
|
|
d)
|
Aggregated
information:
Aggregated volume:
n/a
Aggregated price:
n/a
|
|
e)
|
Date of the
transaction: 23/04/2024
|
|
f)
|
Place of the
transaction: Outside of a trading venue
|
1.
|
Details of the person discharging
managerial responsibilities/person closely
associated
|
|
a)
|
Name: Eddie Johnson
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status: Chief
Financial Officer
|
|
b)
|
Initial
notification/Amendment: Initial Notification
|
3.
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name:
Advanced Medical Solutions Group plc
|
|
b)
|
LEI: 213800HJP6OWOSZI1L74
|
4.
|
Details of the transaction(s): section
to be repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the
financial instrument, type of instrument: Ordinary Shares of
5p
Identification code:
GB0004536594
|
|
b)
|
Nature of the
transactions:
- Grant of LTIPs under the Advanced Medical Solutions Long Term Incentive
Plan
|
|
c)
|
Price(s) and
volume(s):
Sale of
shares:
|
Price(s)
|
Volume(s)
|
|
1. -
|
169,837
|
|
|
d)
|
Aggregated
information:
Aggregated volume:
n/a
Aggregated price:
n/a
|
|
e)
|
Date of the
transaction: 23/04/2024
|
|
f)
|
Place of the
transaction: Outside of a trading venue
|
- End -
For
further information, please visit www.admedsol.com
or
contact:
|
Advanced Medical Solutions Group plc
|
Tel: +44
(0) 1606 545508
|
|
Chris Meredith, Chief Executive
Officer
Eddie Johnson, Chief Financial
Officer
Michael King, Investor
Relations
|
|
|
|
|
|
ICR
Consilium
|
Tel: +44
(0) 20 3709 5700
|
|
Mary-Jane Elliott
/ Lucy
Featherstone
|
AMS@consilium-comms.com
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker)
|
Tel: +44
(0) 20 7597 5970
|
|
Gary Clarence / David
Anderson
|
|
|
|
|
|
HSBC Bank PLC (Broker)
|
Tel: 44
(0) 20 7991 8888
|
|
Sam McLennan / Joe Weaving /
Stephanie Cornish
|
|
About Advanced Medical Solutions Group plc
-
see www.admedsol.com
AMS is a world-leading independent
developer and manufacturer of innovative tissue-healing technology,
focused on quality outcomes for patients and value for payers. AMS
has a wide range of surgical products including tissue adhesives,
sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®,
RESORBA®, LiquiBandFix8® and
Seal-G®. AMS also supplies wound care dressings such as
silver alginates, alginates and foams through its
ActivHeal® brand as well as under white label.
Since 2019, the Group has made five acquisitions: Sealantis, an
Israeli developer of innovative internal sealants; Biomatlante, a
French developer and manufacturer of surgical biomaterials,
Raleigh, a leading UK coater and converter of woundcare and
bio-diagnostics materials, AFS Medical, an Austrian specialist
surgical business and Connexicon, an Irish tissue adhesives
specialist.
AMS's products, manufactured in the
UK, Germany, France, the Netherlands, the Czech Republic and
Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct
sales forces in the UK, Germany, the Czech Republic and Russia. The
Group has R&D innovation hubs in the UK, Ireland, Germany,
France and Israel. Established in 1991, the Group has more than 900
employees. For more information, please see
www.admedsol.com.